Skip to main content

Jim Cramer: What Presidential Transition Trouble Could Mean for Vaccine Rollout

Publish date:
Video Rating:
Video Duration:

Moderna  (MRNA) - Get Moderna, Inc. Report says that it has enough data from its late-stage vaccine trial to submit to independent analysts, and Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Disease, hinted at the possibility of Moderna's vaccine candidate's efficacy being as high as Pfizer's  (PFE) - Get Pfizer Inc. Report

Moderna said the recent surge in U.S. coronavirus infection rates, which rose at a record pace of 140,000 on Wednesday, has meant that the study will include 'substantially more than 53" positive cases, a figure that was targeted as the trigger point for the analysis of the late-stage data. Moderna is using so-called 'messenger RNA' techniques for its vaccine candidate and told investors in September that it had amassed more than 25,000 participants for its clinical-stage trial.

Watch the video above for more.

WATCH: Everything Jim Cramer Is Watching In Markets Thursday

Latest Videos From TheStreet and Jim Cramer:

Related Videos